These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 23696960)

  • 41. Review of the current targeted therapies for non-small-cell lung cancer.
    Nguyen KS; Neal JW; Wakelee H
    World J Clin Oncol; 2014 Oct; 5(4):576-87. PubMed ID: 25302162
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
    Herbst RS
    Semin Oncol; 2003 Feb; 30(1 Suppl 1):30-8. PubMed ID: 12644982
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-Angiogenic Therapy in
    Tan AC; Pavlakis N
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012123
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
    Zhao Y; Wang H; He C
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3653-3664. PubMed ID: 34661758
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Evolution of Therapies in Non-Small Cell Lung Cancer.
    Boolell V; Alamgeer M; Watkins DN; Ganju V
    Cancers (Basel); 2015 Sep; 7(3):1815-46. PubMed ID: 26371045
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecularly targeted therapies in non-small cell lung cancer: The evolving role of tyrosine kinase inhibitors.
    Doval DC; Desai CJ; Sahoo TP
    Indian J Cancer; 2019 Nov; 56(Supplement):S23-S30. PubMed ID: 31793439
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
    Pan G; Ke S; Zhao J
    Target Oncol; 2013 Jun; 8(2):107-16. PubMed ID: 23516098
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).
    Kumarakulasinghe NB; van Zanwijk N; Soo RA
    Respirology; 2015 Apr; 20(3):370-8. PubMed ID: 25689095
    [TBL] [Abstract][Full Text] [Related]  

  • 50. VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.
    Watanabe H; Ichihara E; Kayatani H; Makimoto G; Ninomiya K; Nishii K; Higo H; Ando C; Okawa S; Nakasuka T; Kano H; Hara N; Hirabae A; Kato Y; Ninomiya T; Kubo T; Rai K; Ohashi K; Hotta K; Tabata M; Maeda Y; Kiura K
    Cancer Sci; 2021 May; 112(5):1853-1864. PubMed ID: 33410241
    [TBL] [Abstract][Full Text] [Related]  

  • 51. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.
    Kazandjian D; Blumenthal GM; Chen HY; He K; Patel M; Justice R; Keegan P; Pazdur R
    Oncologist; 2014 Oct; 19(10):e5-11. PubMed ID: 25170012
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
    Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
    Chung C
    J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New insights in drug development for the non-small cell lung cancer therapy.
    Gridelli C; Rossi A; Maione P; Ferrara C; Del Gaizo F; Guerriero C; Nicolella D; Palazzolo G; Falanga M; Colantuoni G
    Front Biosci; 2008 May; 13():5108-19. PubMed ID: 18508573
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence.
    Rothschild SI
    Lung Cancer (Auckl); 2014; 5():51-57. PubMed ID: 28210142
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 58. First-line chemotherapy for advanced-stage non-small-cell lung cancer: focus on docetaxel.
    Ramalingam S
    Clin Lung Cancer; 2005 Dec; 7 Suppl 3():S77-82. PubMed ID: 16384540
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.
    Melosky B; Wheatley-Price P; Juergens RA; Sacher A; Leighl NB; Tsao MS; Cheema P; Snow S; Liu G; Card PB; Chu Q
    Lung Cancer; 2021 Oct; 160():136-151. PubMed ID: 34353680
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting angiogenesis in squamous non-small cell lung cancer.
    Piperdi B; Merla A; Perez-Soler R
    Drugs; 2014 Mar; 74(4):403-13. PubMed ID: 24578213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.